Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

@article{Kavanaugh2007InfliximabMA,
  title={Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.},
  author={Arthur F. Kavanaugh and Gerald G. Krueger and Anna M Beutler and C. Guzzo and Bei Zhou and Lisa T Dooley and Philip J Mease and Dafna D Gladman and Kurt de Vlam and Piet P. Geusens and Charles A Birbara and Dr. Gustav Halter and Christian E. Antoni},
  journal={Annals of the rheumatic diseases},
  year={2007},
  volume={66 4},
  pages={498-505}
}
OBJECTIVE To evaluate the efficacy and safety of infliximab through 1 year in patients with psoriatic arthritis (PsA) enrolled in the IMPACT 2 trial. METHODS In this double blind, placebo controlled, phase III study, 200 patients with active PsA were randomised to receive infusions of infliximab 5 mg/kg or placebo at weeks 0, 2, 6, and every 8 weeks thereafter through 1 year. Patients with persistent disease activity could enter early escape at week 16, and all remaining placebo patients… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

Psoriatic arthritis: a dermatologist's perspective.

American journal of clinical dermatology • 2010
View 8 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…